Edition:
United States

Menlo Therapeutics Inc (MNLO.OQ)

MNLO.OQ on NASDAQ Stock Exchange Global Select Market

11.27USD
1:14pm EDT
Change (% chg)

$0.25 (+2.27%)
Prev Close
$11.02
Open
$11.01
Day's High
$11.45
Day's Low
$11.00
Volume
21,799
Avg. Vol
35,560
52-wk High
$38.68
52-wk Low
$6.99

Summary

Name Age Since Current Position

Steven Basta

51 2018 President, Chief Executive Officer, Director

Kristine Ball

2018 Senior Vice President - Corporate Strategy and Chief Financial Officer

Danine Summers

Senior Vice President - Medical Affairs

Xiaoming Zhang

Senior Vice President - Non-Clinical and CMC

Paul Kwon

Chief Medical Officer

David Collier

51 2016 Director

Biographies

Name Description

Steven Basta

Mr. Steven L. Basta is President, Chief Executive Officer, Director of the Company. Prior to joining Menlo Therapeutics Inc., Mr. Basta served from 2011 to 2015 as CEO of AlterG, Inc. a privately held rehabilitation company which commercializes the AlterG Anti-Gravity Treadmill. From 2002 through 2011, Mr. Basta served as CEO of BioForm Medical, Inc. and its successor, Merz Aesthetics, Inc. Mr. Basta led BioForm’s growth from initial product launch to $80 million in annual revenues at the time of it’s acquisition by Merz, and subsequently led Merz Aesthetics through multiple product launches managing a global business unit which was the #3 worldwide injectable aesthetics business. Prior to Bioform Medical, Mr. Basta served as President and CEO of Gliatech, Inc., a medical device company, VP Business Development and Chief Financial Officer of Creative BioMolecules, Inc., a protein therapy and drug device combination products company, and Executive Director of Product Development for The Immune Response Corporation, a biotechnology company. Mr. Basta also served for two years as an associate with the investment banking firm, Dillon, Read & Co. Inc. ?Mr. Basta received his MBA from the Kellogg Graduate School of Business at Northwestern University, and his bachelor’s degree in biomedical engineering from The Johns Hopkins University.

Kristine Ball

Danine Summers

Ms. Danine Summers is Senior Vice President - Medical Affairs of the Company. Danine has 35 years of experience in the pharmaceutical industry, the last 20 years in dermatology specifically. She started her career in field sales with Merck Sharp & Dohme and then moved on to American Scientific Products and Roche Labs. While at Roche Danine completed her MBA and transitioned from sales to marketing. She has 18 years of experience in various areas of Marketing with FCB Healthcare (clients included Syntex, Gilead, Allergan and Neutrogena) and Connetics Pharmaceuticals where she built the marketing department and launched Luxiq, the first product launch for the company. Danine has spent the past 10 years in Medical Affairs and Professional Relations where she has successfully built and managed two Medical Affairs Departments. Further, she has led and/or participated in over 10 product launches.

Xiaoming Zhang

Dr. Xiaoming Zhang, Ph.D., is Senior Vice President - Non-Clinical and CMC of the Company. He has more than 20 years of experience in discovery and development of new molecular entities across multiple therapeutic areas. Prior to joining Menlo Therapeutics Inc., he was a venture partner at Velocity Pharmaceutical Development, where he played an integral role in the launching and building of several project focused companies, including Menlo Therapeutics Inc., Corsair and Spitfire. In 2010, he cofounded Theron Pharmaceuticals, a clinical stage company developing a best-in-class bronchodilator for the treatment of COPD and uncontrolled asthma. He was previously the Senior Director of Chemistry at CoMentis Inc. In this capacity, he spearheaded cognition research effort targeting Alzheimer’s disease and cognitive deficit associated with schizophrenia. Previously, Dr. Zhang served as Director of Medicinal Chemistry at Millennium Pharmaceuticals, Portola and ARYx, where he successfully led the discovery and development of a number of new molecular entities, notably elinogrel and tecarfarin. Earlier in his career, Dr. Zhang was a research scientist and program leader at Roche. Dr. Zhang received a PhD from University of Maryland, College Park, in the field of synthetic organic chemistry and pursued postdoctoral research at University of California, Berkeley. He is an inventor on 25 US patents.

Paul Kwon

Dr. Paul S. Kwon is Chief Medical Officer of the Company. From 2010 to 2015, Dr. Kwon was Chief Medical Officer at Nora Therapeutics from, a biotechnology company focused on developing therapeutics to address significant unmet needs in reproductive medicine. At Nora, he led development of a clinical-stage molecule for the treatment of repeated implantation failure and recurrent miscarriage. From 2003 to 2009, Dr. Kwon held numerous positions at Genentech, where he was most recently head of the nononcology early clinical development group and oversaw clinical development of molecules from pre-IND through phase 2 in multiple therapeutic areas, including rheumatology, neurology, cardiovascular disease and ophthalmology. In addition, he managed the medical groups for two post-marketed franchises in cardiovascular and metabolic disease. Dr. Kwon was in clinical practice as a dermatologist from 2001 to 2003 and 2009 to 2010 with the Permanente Medical Group in Northern California, where he also served as a consultant for the Permanente Technology Group. Prior to this position, he was product manager and later director of business development for iMedica Corp, a healthcare IT firm in Mountain View, CA. From 2004 to 2014, Dr. Kwon served on the faculty at the University of California at San Francisco as Assistant Clinical Professor of Dermatology. Dr. Kwon received his B.A. in human biology from Stanford University, and his M.D. from the University of California at San Francisco. He is a diplomate of the American Board of Dermatology and a fellow of the American Academy of Dermatology.

David Collier

Dr. David J. Collier M.D., is Director of the Company. David is Chief Executive Officer of Velocity Pharmaceutical Development and Managing Director of Presidio Partners. As CEO of Velocity Pharmaceutical Development (VPD), Dr. Collier is pioneering a new business model for the development of promising drug candidates. VPD acquires the rights to individual therapeutic drug candidates from biotechnology companies, academia, and pharmaceutical companies, and invests in their development through clinical proof-of-concept (generally phase 2). Following proof-of-concept, VPD seeks to sell each drug asset to a major pharmaceutical company. VPD is structured as a holding company, owning a portfolio of virtual companies, each of which develops a single drug candidate, all managed by a single expert team. This development team included several highly experienced former Chief Medical Officers from the biotechnology industry. Dr. Collier joined Presidio Partners in 2001 to focus on investments in biotechnology companies developing drugs through clinical trials across many different therapeutic areas. Examples include Ardelyx (minimally-absorbed drugs acting on the GI tract), Bayhill Therapeutics (autoimmune disorders), Arcion Therapeutics (neuropathic pain), Altus Pharmaceuticals (malabsorption in cystic fibrosis) and Sorbent Therapeutics (congestive heart failure). Dr. Collier currently serves as Chairman of the Board of two Presidio Partners drug development portfolio companies and as a board member of three others. Before joining Presidio Partners, David was a Managing Director at Burrill & Co., a private merchant bank focused exclusively on life science companies, where he played a leading role in the management of the company’s life science venture capital funds. Dr. Collier holds an M.D. from the University of Pennsylvania School of Medicine, an M.B.A. from the Wharton School, and a B.A. in Physics from Wesleyan University.